Background: Cardiovascular disease is the leading cause of death after kidney transplant. Screening for coronary artery disease is integral to pretransplant evaluation, although the relative performance of different tests is uncertain.
C
ardiovascular disease is the leading cause of death in patients after kidney transplant. 1 Presurgical detection of coronary artery disease (CAD) aims to decrease cardiac morbidity and mortality in potential kidney transplant recipients by identifying those with significant cardiovascular disease warranting intervention before transplant. 2 Severe CAD is associated strongly with increased risk of future myocardial infarction. 3, 4 CAD can be detected using either coronary angiography or noninvasive investigations, such as stress echocardiography and myocardial perfusion scintigraphy. Although coronary angiography is the reference standard investigation, it is both costly and invasive. In addition to known potential risks, such as arrhythmia, myocardial infarction, and stroke, complications such as nephrotoxicity and femoral artery injury are particularly troublesome in patients with chronic or end-stage kidney disease awaiting kidney transplant.
Noninvasive screening tests, such as stress echocardiography and myocardial perfusion scintigraphy, have moderate sensitivity and specificity in detecting significant CAD in the general population and are poten-tially useful in triaging patients for coronary angiography. 5, 6 However, it is uncertain whether the diagnostic performance of these tests in the general population can be generalized to potential kidney transplant recipients. Patients with chronic kidney disease are frequently hypertensive and more likely to have cardiomyopathy and calcific vascular disease in addition to atherosclerosis, all of which may alter diagnostic test performance compared with the general population.
Clinical practice varies considerably in the selection of patients for testing (from screening only those with significant risk factors to screening all candidates) and choice of screening tests (functional tests, such as dobutamine stress echocardiography, myocardial perfusion scintigraphy, and stress electrocardiography vs radiographic tests, such as calcium scoring and computed tomography [CT] coronary angiography). 7 Three major clinical practice guidelines produced by the American Society of Transplantation, 2 United Kingdom Renal Association, 8 and Canadian Society of Transplantation 9 advise cardiac stress testing in potential transplant recipients with symptoms or significant risk factors, but do not give a recommendation regarding choice of particular screening test other than the test should be determined by local availability and expertise. We performed a systematic review of the diagnostic test accuracy of noninvasive cardiac screening tests compared with coronary angiography in detecting significant CAD in potential kidney transplant recipients. We also aimed to assess the relative diagnostic performance of different screening tests.
METHODS

Search Strategy
We searched MEDLINE (through OvidSP) and EMBASE (through OvidSP) from inception (last search, January 2010) without language restriction, using key words and text word terms for kidney transplant and index tests (full search strategy available in Item S1, provided as online supplementary material). 10, 11 To locate studies not indexed in MEDLINE or EMBASE, we included citation tracking through Web of Science and checked bibliographies of relevant identified studies.
We included all cross-sectional studies, cohort studies, and randomized controlled trials that compared the accuracy of any cardiac test used for investigating CAD with coronary angiography in adults considered potential candidates for kidney transplant at the time of testing. We defined significant CAD as the presence of Ն50% stenosis in at least 1 epicardial coronary artery detected using coronary angiography. Index tests included any form of stress echocardiography, myocardial perfusion scintigraphy, exercise stress electrocardiography, electron beam CT, CT coronary angiography, magnetic resonance angiography, digital subtraction fluorography, and cardiopulmonary exercise testing. We excluded studies that investigated the accuracy of cardiac tests in patients with end-stage kidney disease who were not transplant candidates (ie, unselected dialysis patients not undergoing pretransplant assessment).
Using a structured template for each study, we extracted details for trial design, setting, definition of CAD (percentage of stenosis on coronary angiogram), prevalence of cardiovascular risk factors in the study population (hemodialysis, end-stage kidney disease, diabetes, male sex, hypertension, smoking history, and symptomatic chest pain), and details of the index test. We assessed the method quality of included primary studies using a modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool as outlined by the Cochrane Collaboration. 12, 13 Two authors (L.W.W. and M.A.F.) independently performed all search and data abstraction steps, with arbitration by a third reviewer when disagreement arose.
Quantitative Data Synthesis
We calculated test performance for detecting CAD of each index test compared with coronary angiography and showed these results as paired forest plots of sensitivity and specificity and studyspecific estimates of sensitivity and specificity in receiver operating characteristic (ROC) space for each index test. We conducted preliminary summary ROC curve analyses using the MosesLittenberg method to investigate the diagnostic performance of each index test using Review Manager, version 5.0 (The Cochrane Collaboration, www.cc-ims.net/revman) and then fitted hierarchical summary ROC curve models using SAS, version 9.2 (SAS Institute Inc, www.sas.com) using the approach described by Macaskill. 14 The hierarchical summary ROC model, proposed by Rutter and Gatsonis 15 in 2001, overcomes a number of limitations of the Moses-Littenberg method. It allows estimation of betweenstudy heterogeneity and also accounts for the precision of study estimates. 16 When test comparisons had 5 or more studies, we used the hierarchical summary ROC model to make inferences about diagnostic accuracy and heterogeneity in test performance. The hierarchical summary ROC model used study-specific estimates of sensitivity and specificity to estimate the position and shape of the summary curve, which we defined using 3 parameters: threshold (the underlying test positivity rate, a proxy for the cutoff point that defined a positive test result), accuracy (the log diagnostic odds ratio [OR]), and shape (the dependence of accuracy on threshold). Because each study provided an estimate for threshold and accuracy, we assumed these to be random effects in the model. When there was no evidence of an association between accuracy and threshold, we considered the summary curve symmetric and its position defined by a constant diagnostic OR. We used model estimates to obtain summary estimates for sensitivity, specificity, diagnostic OR, and their 95% confidence intervals (CIs) for each index test. The corresponding area under the curve (AUC) also was computed from the diagnostic OR.
We performed paired comparisons of test performance between alternative index tests when comparisons between tests occurred in the same (direct comparison) or different study populations (indirect comparison). We included a covariate of test type in the modeling to assess whether the summary ROC curves differed in overall accuracy. We initially assumed equal variances for random effects for the tests, but extended the models to allow for unequal variances for random effects if required.
To investigate potential heterogeneity, we investigated factors that influence diagnostic accuracy other than true test performance, including method quality and study design, characteristics of the underlying population, and characteristics of the index and reference test by applying separate hierarchical summary ROC models to different subgroups of studies and through the addition of covariates to the hierarchical model. We also performed subgroup analyses for studies that avoided verification bias, used a reference standard of Ն70% stenosis on coronary angiography, or consisted of only patients with diabetes mellitus.
This research was conducted as part of a Cochrane systematic review of diagnostic test accuracy evaluating the performance of cardiac testing in potential kidney transplant recipients.
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RESULTS
Studies Included for Analysis
We identified 20 reports of 19 studies for inclusion in the review (see Fig 1 for details of search results and exclusions). One study could not contribute to meta-analysis because it reported results per coronary vessel and not per patient. The diagnostic and treatment pathway is at the patient level, and inclusion of vessel-level analysis leads to inappropriate weighting in the combined analysis and the potential for bias due to clustering of results within patients. 18 One study was reported twice. 19, 20 Table  1 lists characteristics of the 18 studies included in the meta-analysis. Four of these included studies compared more than 1 test versus coronary angiography and therefore could contribute data to more than 1 test comparison. [20] [21] [22] [23] Results of the validity assessment appear in Fig 2. Only 9 (50%) studies provided sufficient information to allow scoring for all 11 method items included in the modified QUADAS tool. Many studies did not explicitly report whether the index or reference tests were performed in a blinded manner, 4 (22%) did not report blinding for reference test, and 3 (17%) did not report blinding for index test. Furthermore, partial verification was present in 2 (11%) studies.
A forest plot of study-specific estimates of sensitivity and specificity of each test is shown in Fig 3 . Figure 4 shows the summary ROC plot of sensitivity and specificity for all studies identified and included in the meta-analysis by test comparison.
Myocardial Perfusion Scintigraphy
Seven studies (317 participants) evaluated myocardial perfusion scintigraphy. [21] [22] [23] [24] [25] [26] [27] The sensitivity of myocardial perfusion scintigraphy varied from 29%-92%, and specificity, from 50%-88%. Pooled summary estimates showed that myocardial perfusion scintigraphy had a diagnostic OR of 7.68 (95% CI, 1.99-29.67) and AUC of 0.80 (95% CI, 0.61-0.91). Pooled sensitivity was 0.69 (95% CI, 0.48-0.85), and specificity was 0.77 (95% CI, 0.59-0.89).
All studies avoided partial verification. Only 1 study did not use a reference threshold of Ն70% stenosis, but instead used a threshold of Ն50% stenosis. 25 There was strong evidence of heterogeneity in the 6 studies that used a Ն70% threshold for diagnosing significant CAD (I 2 ϭ 79%; P Ͻ 0.001). Three studies [23] [24] [25] included only patients with diabetes mellitus and had sensitivity ranging from 63%-85% and specificity ranging from 50%-79%. Removing these studies from the main analysis did not account for all heterogeneity (I 2 ϭ 66%; P ϭ 0.03). One study that used tachycardia pacing to ensure diagnostic myocardial perfusion scintigraphy in some patients had much higher sensitivity and specificity compared with the other studies and accounted for much of the heterogeneity in meta-analysis (I 2 ϭ 34%; P ϭ 0.2 when this study was removed from the remaining group of studies).
27
Dobutamine Stress Echocardiography
Eleven studies (690 participants) compared dobutamine stress echocardiography with angiography. [20] [21] [22] [28] [29] [30] [31] [32] [33] [34] [35] Using induced wall motion abnormalities during dobutamine stress as a positive result indicating CAD, the sensitivity of dobutamine stress echocardiography varied from 44%-96%, and specificity, from 60%-100%. Overall, dobutamine stress echocardiography had a diagnostic OR of 30.98 (95% CI, 10.66-90.03) and AUC of 0.92 (95% CI, 0.83-0.96). Pooled sensitivity was 0.80 (95% CI, 0.64-0.90) and specificity was 0.89 (95% CI, 0.79-0.94). One study also investigated the relationship between peak systolic velocity during dobutamine stress echocardiography and CAD. 34 This study reported that a Յ50% increase in peak systolic velocity with exercise during dobutamine stress echocardiography was associated with Ն70% stenosis on coronary angiography (sensitivity, 86%; specificity, 88%).
In the group of studies that used the higher threshold of Ն70% stenosis and in which partial verification was avoided, pooled sensitivity was 0.78 (95% CI, 0.59-0.90) and specificity was 0.87 (95% CI, 0.75-0.94), with pooled diagnostic OR of 24.40 (95% CI, 7.19-82.78) and AUC of 0.90, but there was evidence of heterogeneity among the studies (I 2 ϭ 67%; P ϭ 0.001). Excluding 3 studies 28, 32, 33 that had a reference test diagnostic threshold of Ն50% stenosis, heterogeneity was increased (I 2 ϭ 73%; P Ͻ 0.001). The remaining studies were similar in performance of the index test and interpretation of test results, but 2 studies that had the highest proportion of patients who were symptomatic with chest pain accounted for most heterogeneity, with an I 2 value decreasing to 0% when these 2 studies were removed. 20, 34 We could not investigate any relationship between diagnostic accuracy and prevalence of CAD more formally because we were limited by the small number of studies and not all studies reported the proportion of symptomatic patients. Only 1 study consisted entirely of patients with diabetes mellitus, with sensitivity of 47% and specificity of 95%.
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Other Tests
Only 2 studies (129 participants) compared exercise stress electrocardiography with coronary angiography. 20, 36 Sensitivity of exercise stress testing varied from 36%-100%, and specificity, from 0%-91% (Fig  3) . In 1 study of 7 participants, only 4 were able to achieve an adequate heart rate and had a diagnostic exercise stress test. The others had nondiagnostic tests because of suboptimal stress. 36 We identified 1 study (35 participants) of exercise radionuclide ventriculography showing sensitivity of 50% and specificity of 67% 23 and 1 study (86 participants) of digital subtraction fluorography showing sensitivity of 78% and specificity of 68% (Fig 3) . 37 
Comparative Analysis: Myocardial Perfusion Scintigraphy Versus Dobutamine Stress Echocardiography
Two studies 21, 22 directly compared myocardial perfusion scintigraphy with dobutamine stress echocardiography (Fig 4) . In both studies, dobutamine stress echocardiography had higher specificity and equiva- Figure 2 . Method design and reporting quality of studies included in meta-analysis according to risk of bias in quality domains assessed using the Quality Assessment of Diagnostic Accuracy Studies tool. Incorporation avoided: the reference standard was independent of the index test. lent or better sensitivity than myocardial perfusion scintigraphy. Both studies used a reference standard threshold of Ն70% stenosis for diagnosing CAD and avoided partial verification. Table 2 and Fig 4 show results of indirect comparison. There was weak evidence that dobutamine stress echocardiography had improved test accuracy over myocardial perfusion scintigraphy (P ϭ 0.07). When we included only studies that avoided partial verification and had a reference threshold Ն70% stenosis on coronary angiography, although dobutamine stress echocardiography appeared to have higher pooled sensitivity (0.78 [95% CI, 0.59-0.90] vs 0.68 [95% CI, 0.43-0.85]) and specificity (0.87 [95% CI, 0.75-0.94] vs 0.80 (95% CI, 0.60-0.91]) than myocardial perfusion scintigraphy, as well as a higher corresponding AUC, these were not statistically significant differences. Variability in accuracy was lower for dobutamine stress echocardiography than myocardial perfusion scintigraphy, with a variance of random effects of diagnostic OR on log scale for dobutamine stress echocardiography of 0.22 versus 0.28. This is shown by the difference in size of the 95% confidence regions in hierarchical summary ROC space (Fig 4) .
DISCUSSION
Both myocardial perfusion scanning and dobutamine stress echocardiography appeared to have moderate sensitivity and specificity in detecting severe coronary artery stenosis. Dobutamine stress echocardiography appeared to have higher sensitivity and specificity than myocardial perfusion scintigraphy, although this difference was not statistically significant. Myocardial perfusion scintigraphy had considerably more variability in test accuracy than dobutamine stress echocardiography.
That dobutamine stress echocardiography had higher specificity than myocardial perfusion scintigraphy is consistent with the principle that reversible systolic dysfunction (detected using dobutamine stress echocardiography) usually occurs after reversible perfusion abnormalities (detected using myocardial perfusion scintigraphy). In the general population, myocardial per- . Summary receiver operator characteristic (ROC) curve plot of sensitivity versus specificity for performance of different tests versus coronary angiography. Each symbol represents a study, with the height and width of each symbol proportional to the inverse standard error of the sensitivity and specificity, respectively. Curves represent summary ROC curves for myocardial perfusion scintigraphy and dobutamine stress echocardiography. Black circles represent the summary estimate of test performance, and the zone outline surrounding it represents the 95% confidence region of this summary estimate. The lines connecting paired myocardial perfusion scintigraphy and dobutamine stress echocardiography studies denote studies that investigated the accuracy of myocardial perfusion scintigraphy and dobutamine stress echocardiography in the same study population (direct comparison). Note: Percentage of coronary artery stenosis assessed using coronary angiography. Abbreviations: AUC, area under the curve; CI, confidence interval; DOR, diagnostic odds ratio; DSE, dobutamine stress echocardiography; MPS, myocardial perfusion scintigraphy.
a P values for this variable were calculated using the likelihood ratio test in SAS (PROC NLMIXED) and represented the final P value obtained from a backward elimination approach used to eliminate nonsignificant terms from the original hierarchical model.
We showed that myocardial perfusion scintigraphy had much larger variability in test accuracy than dobutamine stress echocardiography, probably because myocardial perfusion scintigraphy is a more subjective test. Several studies of myocardial perfusion scintigraphy showed considerable inter-and intrapatient result variability, which may limit its diagnostic utility. 39, 40 Variability also is observed in dobutamine stress echocardiography results, which may be caused by variability in local expertise across the different studies.
The reason for the lower sensitivity of myocardial perfusion scintigraphy in transplant recipients compared with the general population is unclear. One possible mechanism is cardiac parasympathetic denervation, particularly in diabetic patients who have chronic kidney failure, which would decrease the relative efficacy of dipyridamole (routinely used in myocardial perfusion scintigraphy) compared with dobutamine (routinely used in stress echocardiography).
Significant heterogeneity was present among studies investigating the same screening test. Given that the underlying prevalence of disease in a population has the potential to alter diagnostic performance, 41 knowledge of the effect of clinical characteristics, such as angina or diabetes, on diagnostic performance would allow for better informed decisions regarding screening and interpretation of results. Although differences in study population characteristics (eg, prevalence of chest pain) and test application (diagnostic test threshold, criteria for positive test, choice of stress agent and stress protocol, and operator variability) likely contributed to heterogeneity, we were hindered from estimating their contributions because of relatively sparse data, which resulted in low power. As a result, we were unable to provide summary measures of diagnostic performance for specific patient subgroups. Sparse directly comparative data also resulted in low power to detect important differences in accuracy between tests. We also were limited by incomplete reporting of baseline characteristics and study design features necessary for scoring method quality, but were able to obtain much of this missing information by contacting study investigators.
Strengths of this work include a comprehensive search strategy to identify both published and unpublished studies, which did not include search filters for diagnostic terms because these terms are of limited utility. 42, 43 Our analytic approach combined results of only studies with similar method characteristics, and using the hierarchical summary ROC model also was a strength. The hierarchical modeling strategy took into account the sampling variability in estimates of sensitivity and specificity (and the correlation between them) within each study when estimating random effects, resulting in estimates of accuracy that provided better estimates of underlying common log ORs.
14 To ensure that findings were generalizable, we included only studies with populations that consisted entirely of potential kidney transplant recipients, and not others with end-stage kidney disease, because by including unselected dialysis patients, one might expect differences in underlying prevalences of CAD, the presence and severity of other comorbid conditions, and clinical rationales for testing. Figure 5 illustrates the applicability of our findings to clinical practice. Patients in the general population presenting with stable chest pain for assessment typically are assigned pretest probabilities of significant CAD of 10%-29% (low risk), 30%-59% (intermediate risk), and 60%-90% (high risk) using risk tables. 44 Both dobutamine stress echocardiography and myocardial perfusion scintigraphy are useful in ruling out CAD in patients considered at low risk of CAD. However, patients with positive stress test results warrant additional investigation using coronary angiography. However, the true discriminating value of both tests (especially dobutamine stress echocardiography) is in detecting CAD in intermediate-risk patients, a category in which many potential kidney transplant recipients belong. Both tests help reclassify patients at intermediate risk into either high or low risk depending on test results. When dobutamine stress echocardiography is used, patients of intermediate risk who tested positive had a posttest probability of 73%-90% (high risk), and those who tested negative had CAD risk downgraded (10%-27%). Both tests, but dobutamine stress echocardiography in particular, function well as triage tests for intermediate-risk transplant candidates, with negative results decreasing the need for further evaluation using coronary angiography. In highrisk patients, a positive noninvasive dobutamine stress echocardiography or myocardial perfusion scintigraphy result confirms the high risk of severe CAD, but a negative result does not conclusively rule out severe CAD. In these patients, one may consider proceeding immediately to coronary angiography and avoid using functional tests. Nevertheless, functional testing may provide additional prognostic information or help prioritize the waiting list of patients referred for coronary angiography in resource-limited areas.
Although asymptomatic patients with certain high-risk coronary lesions (eg, left main or "equivalent" disease and 3-vessel CAD, particularly with left ventricular dysfunction) benefit from revascu-larization regardless of symptoms, 45 the benefit of preoperative revascularization before transplant surgery is questionable. Two randomized controlled trials (CARP 46 [Coronary Artery Revascularization Prophylaxis Trial] and DECREASE-V [Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography study]) did not show a benefit of revascularization in patients with asymptomatic CAD before major vascular surgery. 47 Nevertheless, the diagnosis of angiographically proved significant CAD in transplant candidates bears further implications to patient management. These include consideration of the need for perioperative ␤-blockade, antiplatelet agents, and anticoagulation therapy.
This review identified only 7 studies involving myocardial perfusion scintigraphy and 11 studies involving dobutamine stress echocardiography. Only 2 of these studies directly compared myocardial perfusion scintigraphy and dobutamine stress echocardiography, and we found very few studies involving exercise stress electrocardiography and other screening modalities. Most studies enrolled small numbers of participants. Future large-scale diagnostic accuracy studies, especially those directly comparing myocardial perfusion scintigraphy and dobutamine stress echocardiography, are required to investigate whether there is a difference in performance between these 2 screening modalities. Further studies involving exercise electrocardiography, coronary artery calcification scoring, and CT coronary angiography also may be useful in improving understanding of the role of these screening modalities and their diagnostic performance. With more evidence, economic modeling could be used to examine efficient use of health resources in different settings by examining different clinical management algorithms.
The ability to identify patients at high risk of CAD may not necessarily enable clinicians to predict cardiac event-free survival after transplant. In the postsurgical period, other factors, such as inflammation, sympathetic nervous system activation, hypercoagulability, and hypoxia, contribute to increased cardiac morbidity and mortality. 48 Patients with kidney failure also have abnormal coronary microcirculation and decreased coronary flow reserve, which may result in cardiac ischemic events even in the absence of macrovascular stenoses. 49, 50, 51 Future research examining the ability of functional tests to predict postoperative outcome urgently is needed.
In conclusion, of the noninvasive screening tests available for the detection of CAD in potential kidney transplant candidates, myocardial perfusion scintigraphy and dobutamine stress echocardiography have been studied in detail. Both tests, especially dobutamine stress echocardiography, function well as triage tests for intermediate-risk transplant candidates, with negative results precluding the need for further evaluation using coronary angiography, thereby avoiding unnecessary risk to patients and potentially decreasing health care costs. Current evidence suggests that, when feasible, dobutamine stress echocardiography should be used as the screening investigation of choice over myocardial perfusion scintigraphy.
